Agilon Health (AGL) shares fell nearly 33% in Friday premarket activity, a day after reporting a wider Q3 net loss and missing market expectations.
The company reported a Q3 net loss from continuing operations late Thursday of $0.29 per share, widening from a loss of $0.06 a year earlier.
Analysts polled by Capital IQ expected a GAAP loss of $0.11.
Total revenue for the quarter ended Sept. 30 was $1.45 billion, up from $1.14 billion a year earlier.
Analysts surveyed by Capital IQ expected $1.47 billion.
For Q4, the company expects total revenue of $1.51 billion to $1.53 billion. Analysts polled by Capital IQ expect $1.48 billion.
For 2024, Agilon now expects total revenue of $6.05 billion to $6.07 billion, compared with $6.01 billion to $6.04 billion previously. Analysts surveyed by Capital IQ expect $6.05 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.